Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Guru SonpavdeNeeraj AgarwalGregory Russell PondRebecca J NagyRoberto H NussenzveigAndrew W HahnOliver SartorTheodore Stewart GourdinLakshminarayanan NandagopalElisa M LedetGurudatta NaikAndrew J ArmstrongJue WangMehmet Asim BilenShilpa GuptaPetros GrivasSumanta Kumar PalRichard B LanmanAmirAli TalasazMichael B LillyPublished in: Cancer (2019)
ctDNA frequently was detected in this large cohort of "real-world" patients with mCRPC, and the alterations appeared to be similar to previously reported tumor tissue alterations. A higher number of alterations, and AR and MYC alterations, appear to compromise clinical outcomes, suggesting a role for immune checkpoint inhibitors and novel AR and BET inhibitors in selected patients.